Global Metastatic Breast Cancer Market - 2023-2030

Global Metastatic Breast Cancer Market - 2023-2030

Global Metastatic Breast Cancer market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.

Metastatic breast cancer, also known as stage IV, occurs when breast cancer cells have spread to other parts of the body, such as the bones, lungs, brain, or liver. This process of cancer spreading is called metastasis, which happens when cancer cells break away from the original tumor in the breast and travel to other parts of the body through the bloodstream or the lymphatic system.

Systemic medications, such as chemotherapy, hormonal therapy, targeted therapies, and immunotherapy, are usually used to treat metastatic breast cancer throughout the entire body. In some cases, local treatments, such as surgery or radiation, may also be recommended to target a specific part of the body.

Market Dynamics: Drivers & Restraints

Growing Prevalence

The growing prevalence of metastatic breast cancer is expected to boost the global market growth during the forecast period. For instance, according to the American Society of Clinical Oncology (ASCO), in the United States, around 6% of females have metastatic breast cancer when they are first analyzed.

Breast cancer is the second most typical reason for death from cancer in females in the United States. Also, it is assessed that about 43,700 individuals (43,170 females and 530 males) casualties from this disease will transpire in the United States in 2023. Moreover, according to the American Medical Association, around 20 to 30 percent of early-stage breast cancer evolves as metastatic or stage IV, the most fierce and devastating state of breast cancer, usually ignored until it evolves as challenging to handle.

Furthermore, growing awareness and research activites among other factors are also expected to contribute to the global market growth during the forecast period.

Absence of Efficacious Therapies

However, the absence of efficacious therapies and treatment-related adverse outcomes could restrict the growth of the metastatic breast cancer market during the forecast period. Furthermore, the lack of awareness and professionals are among the additional factors hampering the global market growth..

Segment Analysis

The global metastatic breast cancer market is segmented based on treatment type, route of administration, end user and region.

Immunotherapy Treatment Type is Expected to Dominate Market

Owing to the increasing positive outcomes from clinical investigations and product approvals is expected to boost the segment growth during the forecast period, dominating the global market. For instance, in August 2023, the final analysis of the phase III TROPiCS-02 study published by the Lancet revealed that the antibody-drug conjugate sacituzumab govitecan-hziy persisted to present exceptional advantage for individuals with hormone receptor–positive, HER2-negative metastatic breast cancer when corresponded with classic chemotherapy.

Moreover, in February 2023, Gilead Sciences, Inc. obtained the U.S. Food and Drug Administration (FDA) authorization for its Trodelvy (sacituzumab govitecan-hziy) to treat adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have obtained endocrine-based treatment and at short two other systemic treatments in the metastatic setting.

Geographical Analysis

North America is Expected to Dominate the Global Market

Owing to the presence of key market players in North America holding major shares of the global market through distinct market strategies including mergers, acquisitions, expansions, and securing funding, the region is expected to dominate the global market during the forecast period.

For instance, in March 2023, Pfizer Inc and Seagen formed a final coalition contract following which Pfizer Inc intends to acquire Seagen, a global biotechnology corporation involved in the discovery, development, and commercialization of innovative cancer therapies, for $229 in cash per Seagen share for a whole enterprise worth of $43 billion.

Moreover, in October 2022, PIC Therapeutics, Inc., a Massachusetts headquartered biopharmaceutical corporation committed to designing life-changing therapies for individuals with cancer, secured a $35 million Series A financing conducted by OrbiMed.

COVID-19 Impact Analysis

Due to the COVID-19 pandemic, there was a significant decrease in cancer diagnosis among breast, colon, and rectal cancers in the first few months, according to a study published in JAMA Network Open. Another study published in the European Journal of Epidemiology reported an overall decrease of approximately 37.3% in diagnostic tests during the pandemic, resulting in 27% fewer cancer diagnoses. This decrease in cancer diagnosis has lowered the demand for cancer therapies.

Market Segmentation

By Treatment Type
• Chemotherapy
• Immunotherapy
• Hormone Therapy
• Radiation Therapy

By Route of Administration
• Oral
• Parenteral

By End User
• Hospitals
• Specialty Clinics
• Cancer Research Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In March 2023, Verzenio (abemaciclib) received an expanded indication from the FDA for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at high risk of recurrence when used in combination with endocrine therapy (ET).
• In July 2023, according to initial data from a phase 2 trial being conducted in Europe, Ixabepilone (Ixempra) provided clinical benefit to patients with metastatic breast cancer who had been selected for treatment with the DRP-IXEMPRA companion diagnostic (CDx) candidate.
• In August 2023, the FDA and Eagle Pharmaceuticals reached a consensus in a Type C meeting to determine the next steps for the development of EA-114, a novel formulation of fulvestrant (Faslodex) and an estrogen receptor antagonist used in the treatment of postmenopausal women with breast cancer.

Competitive Landscape

The major global players in the market include Hoffmann-La Roche, Pfizer Inc, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, Eli Lilly and Company, GlaxoSmithKline Plc, AstraZeneca, Amgen Inc., Merck and Co. Inc. and Novartis AG among others.

Why Purchase the Report?
• To visualize the global metastatic breast cancer market segmentation based on treatment type, route of administration, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of metastatic breast cancer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global metastatic breast cancer market report would provide approximately 61 tables, 58 figures and 184 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies